According to the research report titled ‘Global Peanut Allergy Treatment Market Size study, by Drug Type (Injectable Epinephrine and Antihistamines), by Route of Administration (Oral and Injectable), by Distribution Channel (Retail Pharmacies, Hospital Pharmacies and Online Pharmacies) and Regional Forecasts 2021-2027’, available with MarketStudyReport, global peanut allergy treatment market size is anticipated to expand at a strong growth rate during the forecast timeframe of 2021-2027.
 

Global peanut allergy treatment market is mainly driven by increasing prevalence of food allergies. In fact, Foodallergy.org states that around 200,000 people in United States require emergency medical care for allergic responses to food each year.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/4285234/
 

Furthermore, rising usage of innovative therapeutic substances to treat allergies, increasing commercial & scientific activities for R&D, as well as expanding healthcare expenditure are likely to present growth opportunities for businesses in this domain.
 

Despite the positive outlook, limitations such as inadequate knowledge about treatment accessibility, difficulties concerning treatment authorization, and rigid rules & regulations may obstruct the market expansion throughout the anticipated period.
 

Based on drug type, global peanut allergy industry is split into antihistamines and injectable epinephrine. Considering route of administration, the market is bifurcated into oral and injectable. Lastly, the distribution channel segmentation comprises hospital pharmacies, retail pharmacies, and online pharmacies.
 

With respect to regional point of view, North America (U.S., Canada), Europe (UK, Germany, Spain, France, Russia, Italy, Rest of Europe), Asia Pacific (Japan, China, South Korea, India, Australia, Rest of APAC), and Latin America (Mexico and Brazil) are the major geographies highlighted in the document.
 

North America currently leads the industry in terms of share due to high prevalence of peanut allergy and presence of well-established healthcare infrastructure in the region. Whereas, Asia-Pacific industry is expected to grow rapidly owing to inflating number of allergy tests, huge healthcare spending, increasing personal disposable income, and improving awareness in the region.
 

From the competitive perspective, Astellas Pharma Inc., ALK Abell A/S, Cambridge Peanut Allergy Clinic, Regeneron, Kaleo, Inc., Sanofi S.A., Mylan N.V., Pfizer Inc., DBV Technologies S.A., AnaptysBio, Inc., and Stallergenes Greer Ltd. are the major companies influencing the peanut allergy treatment market trends.